Recovery stack: BPC-157 + TB-500
BPC-157 + TB-500 is the most-reported recovery stack. Mechanism complementarity, standard 6-8 week protocol, dosing, and when the stack earns its cost.
Updated May 7, 2026 · 4 min read
The BPC-157 + TB-500 stack is the most-reported peptide combination in the strength community. It pairs two compounds with complementary — not overlapping — mechanisms: BPC-157 drives local repair through angiogenesis and growth-factor signaling, while TB-500 supports systemic recovery through actin reorganization and cell migration. Used together for a 6-8 week cycle, the stack covers both the localized injury and the whole-tissue context it sits in.
This page walks through when the stack actually earns its cost, the standard protocol most users converge on, and what to expect across a typical cycle.
Why these two together
The mechanism story is what makes this stack non-redundant:
| Compound | Primary action | Where it works |
|---|---|---|
| BPC-157 | Local angiogenesis, VEGF / growth-factor upregulation | At and near the injection site |
| TB-500 | Actin sequestration, cell migration, tissue remodeling | Distributed across the body |
You can think of it as local artist plus dispatcher. BPC-157 builds capillary networks and recruits growth factors at the spot you place it. TB-500 mobilizes repair cells across tissues that the local injection can't reach. For a chronic tendinopathy where the inflamed tendon is one part of a larger movement chain that's also struggling, hitting both layers is the rationale.
Standard protocol
The protocol most users converge on:
| Compound | Dose | Cadence | Route |
|---|---|---|---|
| BPC-157 | 250 mcg | Daily | SubQ near affected tissue |
| TB-500 | 2.5 mg | Twice weekly (loading, weeks 1-4) | SubQ systemic |
| TB-500 | 2.5 mg | Once weekly or every 10-14 days (maintenance, weeks 5-8) | SubQ systemic |
Total cycle: 6-8 weeks. Then a 4-8 week off period before reassessing.
For more on each individual peptide's protocol, see BPC-157 dosing protocols and TB-500 dosing protocols.
When the stack earns its cost
Running both peptides isn't free. A typical BPC-157-only 6-week cycle runs roughly $80-150 in research-chem pricing; adding TB-500 pushes the total to roughly $300-500. The stack earns that premium when:
- A chronic tendinopathy hasn't resolved with 6+ weeks of rest, PT, and BPC-157 alone
- Multiple overlapping soft-tissue issues exist (you can't isolate one to inject)
- A hard training block has produced accumulated, hard-to-localize damage
- You've completed a full BPC-157 cycle with only partial improvement
When a single, recent, well-localized injury is the issue, BPC-157 alone is usually the higher-leverage choice. See BPC-157 vs TB-500 for the decision tree.
What to expect over the cycle
Typical reported timeline:
| Week | What users typically report |
|---|---|
| 1-2 | Mild lethargy from TB-500 loading; injection-site reactions; first hints of reduced inflammation |
| 3-4 | Subjective recovery improvement; better morning mobility; pain reduction in the targeted area |
| 5-6 | Most consolidation of effect; tendon-loading tolerance often improves here |
| 7-8 | Diminishing additional improvement; time to reassess |
The stack is not a feel drug. The signal is in how the affected tissue tolerates loading at week 6 vs baseline, not in how you feel the day after injection.
Logistics
Two peptides means two reconstituted vials. You don't mix them in the same syringe — keep separate vials, draw separately. Many users do successive injections at the same site; others rotate sites. Either is fine. The TB-500 loading phase is the more demanding part of the protocol because it adds twice-weekly draws on top of the daily BPC-157 cadence.
Use the reconstitution calculator to dial in exact unit marks for your vial size.
Cycle length and off period
| Phase | Length | Notes |
|---|---|---|
| Cycle | 6-8 weeks | Match to the goal — don't run longer just to use up vials |
| Off | 4-8 weeks | Document subjective effects during this window |
| Reassess | End of off | Did the goal hold? Is another cycle warranted? |
For more on cycle-length reasoning, see cycle length by peptide class.
Side-effect overlap
Running both doesn't double side-effect risk, but it doesn't halve it either. The most-reported overlapping effects:
- Lethargy in week one (more pronounced during TB-500 loading)
- Mild headaches
- Injection-site reactions (more sites, more chances)
- Mild appetite changes
Both peptides promote angiogenesis and tissue regeneration. The cancer-related caveats discussed in the side-effects pillar apply to either peptide alone and to the stack — active or recent malignancy is a reason to talk with a clinician before starting.
Stack mistakes to avoid
- Adding TB-500 mid-cycle to a BPC-157 run — you can't tell which one is doing what
- Stacking before running BPC-157 alone first — establish your baseline single-peptide response
- Running back-to-back stacked cycles without an off period — cumulative angiogenic signaling is the conservative concern
- Skipping the off-period reassessment — drifting from cycle to cycle hides whether either compound is still earning its place
For the broader list, see stacking and cycling mistakes to avoid.